Learn more →
Back to Expert Scholars
dermatologic-oncology / dermatologic-oncologyAdvanced Melanoma

Caroline Robert

卡罗琳·罗伯特

MD, PhD

🏢Institut Gustave Roussy(古斯塔夫·鲁西研究所)🌐France

Head of Dermatology Unit, Professor of Oncology皮肤科主任,肿瘤学教授

95
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Caroline Robert is Europe's foremost melanoma specialist, leading groundbreaking clinical trials of BRAF and MEK inhibitors at Institut Gustave Roussy. She has made defining contributions to targeted therapy and immunotherapy for melanoma, shaping European and global treatment guidelines.

Share:

🧪Research Fields 研究领域

Dermatologic Oncology皮肤肿瘤学
Melanoma黑色素瘤
BRAF/MEK InhibitorsBRAF/MEK抑制剂
Targeted Therapy靶向治疗

🎓Key Contributions 主要贡献

BRAF/MEK Targeted Therapy

Led pivotal European clinical trials of vemurafenib, dabrafenib, and trametinib in BRAF-mutated melanoma, establishing combined BRAF/MEK inhibition as standard of care.

Melanoma Immunotherapy

Conducted landmark pembrolizumab trials in advanced melanoma, demonstrating unprecedented durable responses and contributing to global regulatory approvals.

Melanoma Guidelines

Shaped ESMO clinical practice guidelines for advanced melanoma, integrating biomarker-driven treatment selection and combination therapy strategies across Europe.

Representative Works 代表性著作

[1]

Pembrolizumab versus Ipilimumab for Advanced Melanoma (KEYNOTE-006)

New England Journal of Medicine (2015)

Demonstrated pembrolizumab superiority over ipilimumab in overall survival and progression-free survival, redefining first-line melanoma treatment globally.

[2]

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

New England Journal of Medicine (2015)

Established nivolumab as effective first-line therapy for BRAF wild-type advanced melanoma, expanding immunotherapy options.

[3]

Dabrafenib plus Trametinib versus Vemurafenib for BRAF V600E Melanoma

New England Journal of Medicine (2015)

Confirmed combined BRAF/MEK inhibition superiority over BRAF monotherapy, establishing doublet targeted therapy as standard of care.

🏆Awards & Recognition 奖项与荣誉

🏆European Society for Medical Oncology (ESMO) Lifetime Achievement Award
🏆Society for Melanoma Research Award
🏆French National Academy of Medicine Prize
🏆Gustave Roussy Institutional Excellence Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 卡罗琳·罗伯特 的研究动态

Follow Caroline Robert's research updates

留下邮箱,当我们发布与 Caroline Robert(Institut Gustave Roussy)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment